CD2 and cancer: When comparing the antigen recognition ability of the TCR and CAR using the C9V variant (9 V) of the cancer testis peptide antigen recognized by the 1 G4 TCR and D52N scFv, TCRs utilizing adhesion molecules, such as CD2 or LFA-1, demonstrated greater antigen recognition159.